PIK3CG and chronic myelogenous leukemia, BCR-ABL1 positive: To further determine the clinical implications of PI3K signaling in TKI resistance, we established a CML mouse model by injecting 0.5 x 106 nilotinib resistant K562 cells via the tail-vein into sublethally irradiated (2.5 Gy) triple transgenic NSG-SGM3 (NSGS) mice (male).